Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.43 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.43 |
| ▸ | CTNNB1 | P35222 | 7/20 | 0.42 |
| ▸ | TCF7L2 | Q9NQB0 | 7/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30039 | 0.90 | MAPK1 (0.43) | TACR1MEN1KMT2AGAA | |
| SCHEMBL23618 | 0.86 | HTT (0.44) | HTTSMN1; SMN2KCNQ3KCNQ2PTGER4 | |
| SCHEMBL30795981 | 0.86 | L3MBTL1 (0.49) | HTTSMN1; SMN2KCNQ3KCNQ2PTGER4 | |
| SCHEMBL21060 | 0.86 | L3MBTL1 (0.49) | HTTSMN1; SMN2KCNQ3KCNQ2PTGER4 | |
| SCHEMBL21336 | 0.84 | KCNQ3 (0.45) | HTTSMN1; SMN2KCNQ3KCNQ2PTGER4 | |
| SCHEMBL29259 | 0.84 | CTNNB1 (0.43) | HTTSMN1; SMN2KCNQ3KCNQ2CTNNB1 | |
| SCHEMBL1722444 | 0.84 | SMN1; SMN2 (0.43) | HTTSMN1; SMN2KCNQ3KCNQ2CTNNB1 | |
| SCHEMBL30795613 | 0.84 | KCNQ3 (0.45) | HTTSMN1; SMN2KCNQ3KCNQ2PTGER4 | |
| SCHEMBL22574 | 0.83 | KCNQ3 (0.56) | HTTSMN1; SMN2KCNQ3KCNQ2PTGER4 | |
| SCHEMBL29055 | 0.83 | CTNNB1 (0.45) | HTTSMN1; SMN2KCNQ3KCNQ2CTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2609084-A1 | SUBSTITUTED 2-AMINO-QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2013-07-03 | — | — | EP | claimed |
| US-8470852-B2 | Substituted 2-amino-quinoline-3-carboxamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2013-06-25 | — | — | US | claimed |
| WO-2012025237-A9 | SUBSTITUTED 2-AMINO-QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2013-02-14 | — | — | WO | claimed |
| US-20120220627-A1 | Substituted 2-amino-quinoline-3-carboxamides as KCNQ2/3 modulators | GRUNENTHAL GMBH (DE) | 2012-08-30 | — | — | US | claimed |
| WO-2012025237-A1 | SUBSTITUTED 2-AMINO-QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2012-03-01 | — | — | WO | claimed |
| EP-2609084-A1 | SUBSTITUTED 2-AMINO-QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2013-07-03 | — | — | EP | disclosed |
| US-8470852-B2 | Substituted 2-amino-quinoline-3-carboxamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2013-06-25 | — | — | US | disclosed |
| WO-2012025237-A9 | SUBSTITUTED 2-AMINO-QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2013-02-14 | — | — | WO | disclosed |
| US-20120220627-A1 | Substituted 2-amino-quinoline-3-carboxamides as KCNQ2/3 modulators | GRUNENTHAL GMBH (DE) | 2012-08-30 | — | — | US | disclosed |
| WO-2012025237-A1 | SUBSTITUTED 2-AMINO-QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220627-A1 | Substituted 2-amino-quinoline-3-carboxamides as KCNQ2/3 modulators | KCNQ1, KCNQ2, KCNQ3 | HTT 1457/4885SMN1; SMN2 1809/4885KCNQ3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.